• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by CalciMedica Inc.

    7/8/24 12:48:59 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALC alert in real time by email
    SC 13G 1 calc13g.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    CalciMedica, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.0001

    (Title of Class of Securities)

     

     

    38942Q202

    (CUSIP Number)

     

     

    June 27, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [ ]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 810648105

     

    1.Names of Reporting Persons.

    Laurence W. Lytton

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization USA

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 756,180

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 756,180
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 756,180

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 6.9%

     

    12.Type of Reporting Person (See Instructions) IN

     

     2 
    CUSIP No. 810648105

    Item 1.

     

    (a)Name of Issuer

    CalciMedica, Inc.

     

    (b)Address of Issuer's Principal Executive Offices

    505 Coast Boulevard South, Suite 307, La Jolla, CA 92037

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Laurence W. Lytton

    (b)The principal business office of the Filers is located at:

    467 Central Park West
    New York, NY 10025

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to shares of Common Stock, par value $0.0001of the Issuer (the "Stock").

     

    (e)The CUSIP number of the Issuer is: 38942Q202
     3 
    CUSIP No. 810648105
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[ ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E).

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page.

     

    The shares of Common Stock beneficially owned by the reporting person consist of 494,878 shares of Common Stock and warrants to acquire 261,302 shares of Common Stock. The percentages reported in this Schedule 13G are based on 10,749,065 shares of Common Stock outstanding as of May 7, 2024, as reported in the Form 10-Q filed by the Issuer on May 13, 2024.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: July 8, 2024

     

     

    /s/ Laurence W. Lytton

    Laurence W. Lytton

     

     

     

    Get the next $CALC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CALC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CALC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

    LA JOLLA, Calif., Sept. 2, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 3:30 p.m. ET. A live webcast of the presentation can be accessed in the "IR Events and Pr

    9/2/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

    Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in early 2026  Productive initial meeting with the FDA on Auxora in acute pancreatitis (AP); conversations continue, with alignment on a pivotal trial anticipated around the end of 2025 Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., Aug. 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported fin

    8/12/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

    LA JOLLA, Calif., July 8, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025, at 2:00 p.m. ET. A live webcast of the presentation can be accessed in the "IR

    7/8/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    SEC Filings

    View All

    SEC Form 10-Q filed by CalciMedica Inc.

    10-Q - CalciMedica, Inc. (0001534133) (Filer)

    8/12/25 4:15:33 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CalciMedica, Inc. (0001534133) (Filer)

    8/12/25 7:30:28 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CalciMedica Inc.

    SCHEDULE 13G/A - CalciMedica, Inc. (0001534133) (Subject)

    8/5/25 7:32:14 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF BUSINESS OFFICER Roberts Eric W bought $15,600 worth of shares (5,000 units at $3.12) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/15/25 12:31:52 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $7,378 worth of shares (2,343 units at $3.15) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/11/25 12:00:07 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $28,532 worth of shares (10,000 units at $2.85) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/2/25 1:05:22 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF BUSINESS OFFICER Roberts Eric W bought $15,600 worth of shares (5,000 units at $3.12) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/15/25 12:31:52 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $7,378 worth of shares (2,343 units at $3.15) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/11/25 12:00:07 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $28,532 worth of shares (10,000 units at $2.85) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/2/25 1:05:22 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    Leadership Updates

    Live Leadership Updates

    View All

    CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

    Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three recent medical meetings, including a post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia, which showed a 62.7% relative reduction in mortality for Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., May 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

    5/14/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

    Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., March 27, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

    3/27/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

    LA JOLLA, Calif., Jan. 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of Alan Glicklich, M.D. to the Company's Board of Directors effective on January 15, 2025. Dr. Glicklich has more than 20 years of experience in the biotechnology industry and currently serves as Chief Medical Officer of Nuvig Therapeutics.

    1/14/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    Financials

    Live finance-specific insights

    View All

    CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

    Statistically significant 100% reduction (p = 0.0027) in new-onset severe respiratory failure and 64.2% reduction (p = 0.0476) in new-onset persistent respiratory failure in combined high and medium dose Auxora patients versus combined low dose Auxora and placebo patients Statistically significant stratified win ratio of 1.640 (p = 0.0372) for high dose Auxora compared to placebo Clinically meaningful reduction observed for high dose Auxora patients compared to placebo in additional key endpoints: new-onset necrotizing pancreatitis and time to medically indicated discharge Conference call and webcast to review full data set from the Ph2b CARPO trial to be held at 12 p.m. ET/ 9 a.m. PT LA JOL

    10/30/24 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

    Conference call and webcast to be held Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT LA JOLLA, Calif., Oct. 28, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a call on Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT to review the full data set and win ratio analysis from the Company's Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). Prof. Robert Sutt

    10/28/24 4:05:00 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

    Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE, Phase 2 trial of Auxora™ in severe acute kidney injury (AKI), with data expected in 2025 LA JOLLA, Calif., Aug. 12, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica or the Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended June 30, 2024.

    8/12/24 4:10:00 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by CalciMedica Inc.

    SC 13D - CalciMedica, Inc. (0001534133) (Subject)

    11/26/24 6:03:55 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CalciMedica Inc.

    SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

    11/14/24 3:32:39 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CalciMedica Inc.

    SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

    11/14/24 1:05:20 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care